Doç. Dr. Ezgi Değerli

Doctor and researcher Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi İstanbul
Breast NeoplasmsNeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsObesitySkin Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 7 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Neoplasms 4 publications
  • Carcinoma, Non-Small-Cell Lung 3 publications
  • Lung Neoplasms 3 publications
  • Obesity 2 publications
  • Skin Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • InstitutionBakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 7 publications · Model version —From source
  • Publications38 publicationsOpenAlex, Europe PMCFrom source
  • ORCID0000-0002-8664-5701ORCIDFrom source
  • Last synchronised5 November 2026 08:55https://bakirkoysadikonukeah.saglik.gov.tr/TR-1498675/doktorlarimiz.html#ezgi-degerlisaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

38 publications

  1. Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy

    Medicina, 2026

    DOI 10.3390/medicina62010200 PMID 41597486 Open-access full textSource: OpenAlex

  2. Pathological Response and Survival Outcomes Following Neoadjuvant Chemotherapy in HR+/HER2- Breast Cancer: Real-world Experience

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-3-9 Open-access full textSource: OpenAlex

  3. Prognostic Value of BMI in Patients with Metastatic Cervical Cancer:A Retrospective Study From Turkey

    OncoTargets and therapy, 2026

    DOI 10.2147/ott.s622194 PMID 42644128 Open-access full textSource: Europe PMC

  4. Prognostic value of CT-measured baseline tumor volume in nivolumab-treated metastatic renal cell carcinoma

    Tumori, 2026

    DOI 10.1177/03008916261490843 PMID 42847292 Source: Europe PMC

  5. Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy

    Medicina, 2025

    DOI 10.3390/medicina61071168 PMID 40731799 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  6. Clinical Analysis of Multiple Primary Malignant Tumors: A Single-Center Experience

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25022 Open-access full textSource: OpenAlex

  7. Neutrophil–Lymphocyte Ratio and Prognostic Nutritional Index Predict Prognosis for Definitive Chemoradiotherapy in Cervical Cancer

    Indian Journal of Gynecologic Oncology, 2025

    DOI 10.1007/s40944-025-01029-6 Source: OpenAlex

  8. Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-91102-z PMID 39984593 11 citations (Europe PMC) Open-access full textSource: OpenAlex

  9. The Relationship Between Changes in the Neutrophil-Lymphocyte Ratio (NLR) and Radiological Progression in Cervical Cancer

    Istanbul Medical Journal, 2025

    DOI 10.4274/imj.galenos.2025.59254 Open-access full textSource: OpenAlex

  10. The Relationship Between Hemoglobin to Albumin Ratio and Disease-Free Survival in Patients with Locally Advanced Nasopharyngeal Cancer Treated with Chemoradiotherapy

    Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy, 2025

    DOI 10.4274/bmj.galenos.2025.2025.3-8 Open-access full textSource: OpenAlex

View all 38 publications